Renergen has developed the ground-breaking Cryo-Vacc, which enables the safe transportation of vaccines at the required extremely low temperatures and for periods of up to 30 days, without the need for any power supply.
Renergen is proud to have developed this innovative concept, at a time when the world is seeking solutions on how to overcome the COVID-19 pandemic. Defeating the virus will take collaboration and for that reason we are actively looking for partners with significantly more resources than us to roll-out the large-scale manufacture of the Renergen Cryo-Vacc – in particular global logistics companies who are responsible for the transportation of biologics and vaccines.
With the Renergen Cryo-Vacc, transportation of these vaccines can be achieved in a cost effective manner, given the relatively small size and weight. Depending on where and how the helium is sourced, the operating cost of the case should be under US$3 per month for each dose.
Importantly, moving the Renergen Cryo-Vacc between origin and destination more frequently will significantly reduce this operating cost.